Annals of Surgical Oncology

, Volume 11, Issue 10, pp 934–940

Expression of Cancer-Testis Antigen (CTA) Genes in Intrahepatic Cholangiocarcinoma

Authors

  • Tohru Utsunomiya
    • Department of Surgery, Medical Institute of BioregulationKyushu University
  • Hiroshi Inoue
    • Department of Surgery, Medical Institute of BioregulationKyushu University
  • Fumiaki Tanaka
    • Department of Surgery, Medical Institute of BioregulationKyushu University
  • Hiroshi Yamaguchi
    • Department of Surgery, Medical Institute of BioregulationKyushu University
  • Mitsuhiko Ohta
    • Department of Surgery, Medical Institute of BioregulationKyushu University
  • Masahiro Okamoto
    • Department of Surgery, Medical Institute of BioregulationKyushu University
  • Koshi Mimori
    • Department of Surgery, Medical Institute of BioregulationKyushu University
    • Department of Surgery, Medical Institute of BioregulationKyushu University
    • Department of Surgery, Medical Institute of BioregulationKyushu University
Original Article

DOI: 10.1245/ASO.2004.01.029

Cite this article as:
Utsunomiya, T., Inoue, H., Tanaka, F. et al. Ann Surg Oncol (2004) 11: 934. doi:10.1245/ASO.2004.01.029

Abstract

Background:Cancer-testis antigens (CTA), such as MAGE, are selectively expressed in various types of human neoplasms but not in normal tissues other than testis. This characteristic feature of CTA makes them promising antigens for cancer-specific immunotherapy.

Methods: We investigated the expression of five genes, including MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4, in 20 surgical samples of intrahepatic cholangiocarcinomas (IHCC) using reverse transcription-polymerase chain reaction. To visualize the localization of MAGE proteins, we performed immunohistochemical studies. Furthermore, the correlation between the CTA expression and DNA methylation status was studied in three bile duct cancer cell lines.

Results: Expression of MAGE-1, MAGE-3, NY-ESO-1, SCP-1, and SSX-4 was recognized in 4, 4, 2, 6, and 3 of all 20 cases, respectively. In contrast, the expressions of five genes were not recognized at all in the corresponding normal tissues. In 10 cases (50%), the tumors expressed at least one of the five CTA. An immunohistochemical analysis of MAGE proteins demonstrated homogenous or focal distributions in cytoplasm of the IHCC. Using a demethylating agent, MAGE-1, NY-ESO-1, SCP-1, and SSX-4 were induced in two of three cell lines, whereas MAGE-3 was not.

Conclusions: Half of the tumor tissues of IHCC expressed at least one of the CTA. Some of the patients with IHCC, therefore, should be candidates for potentially useful cancer-specific immunotherapy.

Key Words:

MAGECancer-testis antigenImmunotherapyCancer vaccineCholangiocarcinoma

Copyright information

© The Society of Surgical Oncology, Inc. 2004